Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Adam Feuerstein May 11, 2022
Roche said Wednesday that its experimental cancer immunotherapy directed against a target called TIGIT suffered its second consecutive setback, failing this time to slow tumor growth in a large study involving the most common type of lung cancer.
The study’s disappointing outcome is a significant blow to the Swiss pharma giant’s effort to develop the antibody treatment called tiragolumab — the most important cancer drug in its research pipeline, and a linchpin in its strategy to greatly expand the pool of patients who might benefit from treatments that work by activating the immune system to find and kill tumors.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Senior Writer, Biotech
Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast.
biotechnology
cancer
pharmaceuticals
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
By Matthew Herper
By Matthew Herper
advertisement
By Damian Garde
By Allison DeAngelis
By Megan Molteni
Reporting from the frontiers of health and medicine